Assessment of Minimal Residual Disease in Standard-Risk AML.
Nottingham, United Kingdom. In N Engl J Med, Feb 2016
Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during remission.
Minimal Residual Disease in NPM1-Mutated AML.
Milwaukee, United States. In N Engl J Med, Feb 2016
UNASSIGNED: One of the most important discoveries in the treatment of acute leukemia is that the presence of minimal residual disease is an independent prognostic factor for the duration of remission and survival.
Molecular therapy for acute myeloid leukaemia.
New York City, United States. In Nat Rev Clin Oncol, Jan 2016
Indeed, risk status in patients with this disease has classically been based on cytogenetic findings; however, additional molecular characteristics have been shown to inform risk assessment, including FLT3, NPM1, KIT, and CEBPA mutation status.
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.
San Diego, United States. In Bioorg Med Chem Lett, Dec 2015
Expression of ALK in normal human tissues is only found in a subset of neural cells, however it is involved in the genesis of several cancers through genetic aberrations involving translocation of the kinase domain with multiple fusion partners (e.g., NPM-ALK in anaplastic large cell lymphoma ALCL or EML4-ALK in non-small cell lung cancer) or activating mutations in the full-length receptor resulting in ligand-independent constitutive activation (e.g., neuroblastoma).
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
More papers using
Bologna, Italy. In Clin Lymphoma Myeloma Leuk, Jun 2015
Mutations in genes other than BCR-ABL1 include ASXL1, TET2, RUNX1, DNMT3A, EZH2, and TP53 in chronic phase patients and RUNX1, ASXL1, IKZF1, WT1, TET2, NPM1, IDH1, IDH2, NRAS, KRAS, CBL, TP53, CDKN2A, RB1, and GATA-2 mutations in advanced phase patients.